Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience

Authors Glen J Pearson, Kari L Olson, Nicole E Panich, Sumit R Majumdar, Ross T Tsuyuki, et al

Published Date August 2008 Volume 2008:4(5) Pages 1127—1135

DOI http://dx.doi.org/10.2147/VHRM.S3748

Published 18 August 2008

Glen J Pearson1,5, Kari L Olson6, Nicole E Panich1, Sumit R Majumdar2,5, Ross T Tsuyuki1,4, Dawna M Gilchrist2,5, Ali Damani4, Gordon A Francis3,5

The MILLARR Study (Maintenance of Improved Lipid Levels Following Attendance at a Cardiovascular Risk Reduction Clinic) 1Department of Medicine, Divisions of Cardiology; 2General Internal Medicine; 3Endocrinology and Metabolism; Faculty of Pharmacy and Pharmaceutical Sciences; 4University of Alberta, Edmonton, Alberta, Canada; 5Cardiovascular Risk Reduction Clinic (CRRC), University of Alberta Hospital, Edmonton, Alberta, Canada; 6University of Colorado Health Sciences Center, Denver, Colorado, USA; 7Family Medicine (Private Practice), Calgary, Alberta, Canada

Background: Specialty cardiovascular risk reduction clinics (CRRC) increase the proportion of patients attaining recommended lipid targets; however, it is not known if the benefits are sustained after discharge. We evaluated the impact of a CRRC on lipid levels and assessed the long-term effect of a CRRC in maintaining improved lipid levels following discharge.

Methods: The medical records of consecutive dyslipidemic patients discharged >6 months from a tertiary hospital CRRC from January 1991 to January 2001 were retrospectively reviewed. The primary outcome was the change in patients’ lipid levels between the final CRRC visit and the most recent primary care follow-up. A worst-case analysis was conducted to evaluate the potential impact of the patients in whom the follow-up lipid profiles post-discharge from the CRRC were not obtained.

Results: Within the CRRC (median follow-up = 1.28 years in 1064 patients), we observed statistically significant improvements in all lipid parameters. In the 411 patients for whom post-discharge lipid profiles were available (median follow-up = 2.41 years), there were no significant differences observed in low-density lipoprotein-cholesterol, total cholesterol (TC), or triglycerides since CRRC discharge; however, there were small improvements in high-density lipoprotein-cholesterol (HDL-C) and TC:HDL ratio (p < 0.05 for both). The unadjusted worst-case analysis (653 patients with no follow-up lipid profiles) demonstrated statistically significant worsening of all lipid parameters between CRRC discharge and the most recent follow-up. However, when the change in lipid parameters between the baseline and the most recent follow-up was assessed in this analysis, the changes in all lipid parameters were significantly improved (p < 0.05).

Conclusions: This study demonstrates that a CRRC can improve lipid levels and suggests that these benefits are sustained once patients are returned to the care of their primary physician.

Keywords: cardiovascular risk factors, dyslipidemia, outcomes, pharmacotherapy, secondary prevention

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Integrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine

Yuzhalin AE, Kutikhin AG

Cancer Management and Research 2012, 4:131-135

Published Date: 23 May 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Synthesis and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by blending with chitosan for neural tissue engineering

Naghavi Alhosseini S, Moztarzadeh F, Mozafari M, Asgari S, Dodel M, Samadikuchaksaraei A, Kargozar S, Jalali N

International Journal of Nanomedicine 2012, 7:25-34

Published Date: 4 January 2012

Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium

Wang B, Jiang W, Yan H, Zhang X, Yang L, Deng L, Singh GK, Pan J

International Journal of Nanomedicine 2011, 6:1443-1451

Published Date: 7 July 2011

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors

Wang Z-Y, Wang L, Zhang J, Li Y-T, Zhang D-S

International Journal of Nanomedicine 2011, 6:871-875

Published Date: 27 April 2011

Impact of a diabetic foot care education program on lower limb amputation rate

Abdullah M Al-Wahbi

Vascular Health and Risk Management 2010, 6:923-934

Published Date: 11 October 2010

Novel opportunities and challenges offered by nanobiomaterials in tissue engineering

Fabrizio Gelain

International Journal of Nanomedicine 2008, 3:415-424

Published Date: 10 August 2008